Investigational Anti-Cancer DNA Therapy Eases Chronic Osteoarthritis Pain in Dogs—Pointing to a New Non-Opioid Path for Humans

The July 31, 2025 feature on Vet Candy highlights a groundbreaking open-label pilot study of Elenagen™, CureLab Oncology’s plasmid DNA therapy originally developed for oncology. Published in Frontiers in Veterinary Science, the study administered ten weekly intramuscular injections to 17 dogs suffering from chronic osteoarthritis. The results were impressive: 90% of the dogs experienced at least a 1‑point decrease in Pain Severity Score and a 2‑point drop in Pain Interference Score, with median scores falling dramatically—from 5.25 to 3.25 and from 7.00 to 3.27, respectively—by day 70. No treatment‑related adverse effects were observed, and blood chemistries remained within normal limits.

Mechanistically, the therapy appears to “reset” aging mesenchymal stem cells (MSCs), reversing their inflammatory state and restoring youthful, anti‑inflammatory function. This, in turn, may break the inflammation–pain cycle at the root — offering a disease‑modifying approach rather than merely symptom relief.

Vet Candy is a leading platform for veterinary professionals and enthusiasts, providing timely insights into innovations within animal health. This article underscores the translational and cross-disciplinary potential of CureLab Oncology’s research. By showcasing Elenagen’s efficacy in alleviating chronic osteoarthritis pain in dogs, the feature positions the therapy as a promising non-opioid, disease-modifying treatment—one that may soon bridge veterinary and human medicine. It reinforces CureLab Oncology’s reputation for pioneering science-based approaches that may benefit both species.